ReviewTherapeutic advances in respiratory disease
Nuclear factor erythroid 2-related factor 2 as targets to treat chronic obstructive pulmonary disease: toward new perspectives.
Review in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) is a common respiratory disease characterized by persistent airflow limitation and driven by interconnected pathways of oxidative stress, inflammation, and cell death. While nuclear factor E2-related factor 2 (Nrf2) is well-established as a central regulator of antioxidant defense, its role in COPD is now understood to be far more extensive. Beyond redox balance, Nrf2 modulates inflammatory responses and critical processes like autophagy, apoptosis, and ferroptosis, highlighting its pleiotropic nature and therapeutic potential. This review delineates the multifaceted functions of Nrf2 in COPD and explores its promise as a target for precision therapy, providing a foundation for future research and drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.